Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 2, 2015, Pages 243-257

  Johnston, Alexander ^a   Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adverse drug reactions; Danger hypothesis; Drug induced agranulocytosis; Hapten hypothesis; Idiosyncratic drug reactions; Inflammasome; Myeloperoxidase; Neutrophil; Reactive metabolites

Indexed keywords

AMINOPHENAZONE; AMODIAQUINE; ANTIBODY; CLOZAPINE; CYTOKINE; DIPYRONE; HAPTEN; INFLAMMASOME; INFLIXIMAB; LEVAMISOLE; OLANZAPINE; PROPYLTHIOURACIL; RITUXIMAB; BIOLOGICAL MARKER; HLA ANTIGEN;

AGE DISTRIBUTION; AGRANULOCYTOSIS; ALLERGIC REACTION; ALTERNATIVE HYPOTHESIS; BONE MARROW CELL; CELL MATURATION; CLINICAL FEATURE; CYTOTOXICITY; DRUG INDUCED DISEASE; DRUG MECHANISM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HAZARD ASSESSMENT; HUMAN; IDIOSYNCRATIC DRUG INDUCED AGRANULOCYTOSIS; IDIOSYNCRATIC DRUG REACTION; IMMUNE RESPONSE; IMMUNE SYSTEM; INCIDENCE; INNATE IMMUNITY; LEUKOCYTE; LYMPHOCYTE TRANSFORMATION TEST; METABOLIC ACTIVATION; METABOLITE; MORTALITY; NEUTROPHIL; NEUTROPHIL COUNT; PATIENT RISK; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; STROMA CELL; SYSTEMATIC REVIEW (TOPIC); ADVERSE DRUG REACTION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

AGRANULOCYTOSIS; ANIMALS; BIOMARKERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HLA ANTIGENS; HUMANS; INFLAMMASOMES; NEUTROPHILS; OXIDATION-REDUCTION;

EID: 84921317358     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.985649     Document Type: Review

References (101)

1. Andrès E, Zimmer J, Affenberger S, et al. Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur J Intern Med 2006;17:529-35
2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004;329:15-19
3. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013;5:779-808
4. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 1999;12:387-95. Review
5. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the extend study on ximelagatran. Thromb Res 2009;123:488-97
6. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-14
7. Metushi IG, Zhu X, Chen X, et al. Mild isoniazid-induced liver injury in humans is associated with an increase in th17 cells and T cells producing IL-10. Chem Res Toxicol 2014;27:683-9
8. Séguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003;3:235-42. Review
9. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21:84-92. Review
10. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007;146:657-65
11. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92
12. Vergani D, Mieli-Vergani G, Alberti A, et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980;303:66-71
13. Metushi IG, Sanders C, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014;59:1084-93
14. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997;27:175-81
15. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997;41:534-40
16. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 2012;52:21-35
17. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4,DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47:945-8
18. Yunis JJ, Corzo D, Salazar M, et al. HLA associations in clozapine-induced agranulocytosis. Blood 1995;86:1177-83
19. Ostrousky O, Meged S, Loewenthal R, et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 2003;62:483-91
20. Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep 2011;13:156-65. Review
21. Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med 2013;5:5
22. Wadelius M, Stjernberg E, Wiholm BE, et al. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 2000;10:35-41
23. Sharma AM, Novalen M, Tanino T, Uetrecht JP. 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash. Chem Res Toxicol 2013;26:817-27
24. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 2008;21:1814-22
25. Nakayama S, Atsumi R, Takakusa H, et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 2009;37:1970-7
26. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 2003;8:832-7. Review
27. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B∗57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012;26:F21-9
28. Lafferty KJ, Gazda LS. Tolerance: a case of self/not-self discrimination maintained by clonal deletion? Hum Immunol 1997;52:119-26. Review
29. Miller JF, Basten A. Mechanisms of tolerance to self. Curr Opin Immunol 1996;8:815-21. Review
30. Landsteiner K, Jacobs J. Studies of the sensitization of animals with simple chemical compounds. J Exp Med 1935;61:643-56
31. Parker CW, Shapiro J, Kern M, Eisen HN. Hypersensitivity to penicillenic acid derivatives in human beings with penicillin allergy. J Exp Med 1962;115:821-38
32. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045. Review
33. Anderson CC, Matzinger P. Danger: the view from the bottom of the cliff. Semin Immunol 2000;12:231-8.discussion 257-344
34. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55
35. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 2000;97:14590-5
36. Matzinger P. An innate sense of danger. Semin Immunol 1998;10:399-415. Review
37. Watts TH, Bertram EM, Bukczynski J, Wen T. T cell costimulatory molecules in anti-viral immunity: potential role in immunotherapeutic vaccines. Can J Infect Dis 2003;14:221-9
38. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol 2008;214:161-78. Review
39. Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Saf 1997;16:1-8. Review
40. Ellrodt AG, Murata GH, Riedinger MS, et al. Severe neutropenia associated with sustained-release procainamide. Ann Intern Med 1984;100(2):197-201
41. Weston JK, Uetrecht J. Activation of inflammasomes by agents causing idiosyncratic skin reactions: a possible biomarker. Chem Res Toxicol 2014;27:949-51
42. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9. Review
43. Chen X, Tharmanathan T, Mannargudi B, et al. A study of the specificity of lymphocytes in nevirapine-induced skin rash. J Pharmacol Exp Ther 2009;331:836-41
44. Tohyama M, Hashimoto K. Immunological mechanisms of epidermal damage in toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol 2012;12:376-82
45. Khan R, Schmidt-Mende J, Karimi M, et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008;36:149-57
46. Bray A. Ethnic neutropenia and clozapine. Aust N Z J Psychiatry 2008;42:342-5
47. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169:483-8
48. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006;188:255-63
49. Kaufman DW, Kelly JP, Jurgelon J, et al. Drugs in the etiology of agranulocytosis and aplastic anemia. Eur J Haematol 1996;57:23-30
50. Andrès E, Maloisel F, Kurtz JE, et al. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med 2002;13:324-8
51. Juliá A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991;79:366-71
52. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-7
53. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005;165:869-74
54. Imbarlina MJ, Sarkar S, Marwah S, et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur Psychiatry 2004;19:506-9
55. Demler TL, Trigoboff E. Are clozapine blood dyscrasias associated with concomitant medications? Innov Clin Neurosci 2011;8:35-41
56. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 2009;84:428-34
57. Uetrecht JP. The role of leukocyte-generated metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992;24:299-366
58. Brown KE, Brunt EM, Heinecke JW. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol 2001;159:2081-8
59. Liu ZC, Uetrecht JP. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 1995;275:1476-83
60. Lai WG, Zahid N, Uetrecht JP. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J Pharmacol Exp Ther 1999;291:292-9
61. Ju C, Uetrecht JP. Oxidation of a metabolite of indomethacin (Desmethyldeschlorobenzoylindo methacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab Dispos 1998;26:676-80
62. Lobach AR, Uetrecht J. Involvement of myeloperoxidase and NADPH oxidase in the covalent binding of amodiaquine and clozapine to neutrophils: implications for drug-induced agranulocytosis. Chem Res Toxicol 2014;27:699-709
63. Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24:613-17
64. Besser M, Vera J, Clark J, et al. Preservation of basophils in dapsone-induced agranulocytosis suggests a possible pathogenetic role for leucocyte peroxidases. Int J Lab Hematol 2009;31(2):245-7
65. Bainton DF, Ullyot JL, Farquhar MG. The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. J Exp Med 1971;134:907-34
66. Fliedner TM, Cronkite EP, Robertson JS. Granulocytopoiesis. I. Senescence and random loss of neutrophilic granulocytes in human beings. Blood 1964;24:402-14
67. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest 1961;40:989-95
68. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol 2010;31:318-24. Review
69. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 1989;339:27-30. Review
70. Moeschlin S, Wagner K. Agranulocytosis due to the occurrence of leukocyte-agglutinins. Acta Haematol 1952;8:29-41
71. Brederoo P, van der Meulen J, Daems WT. Ultrastructural localization of peroxidase activity in developing neutrophil granulocytes from human bone marrow. Histochemistry 1986;84:445-53
72. Maes M, Bosmans E, Kenis G, et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997;26:221-5
73. Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996;16:403-9
74. Pollmacher T, Haack M, Schuld A, et al. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000;34:369-82
75. Ng W, Kennar R, Uetrecht J. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol 2014;27:1104-8
76. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000;58:207-16
77. Ip J, Wilson JX, Uetrecht JP. Testing the hypothesis that vitamin C deficiency is a risk factor for clozapine-induced agranulocytosis using guinea pigs and ODS rats. Chem Res Toxicol 2008;21:869-73
78. Ip J, Uetrecht JP. Testing the hypothesis that selenium deficiency is a risk factor for clozapine-induced agranulocytosis in rats. Chem Res Toxicol 2008;21:874-8
79. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cell signaling and inflammatory disease. Biochim Biophys Acta 2014;1843:2563-82. Review
80. Brach MA, deVos S, Gruss HJ, Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 1992;80:2920-4
81. Sperner-Unterweger B, Gaggl S, Fleischhacker WW, et al. Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 1993;34:536-43
82. Guest I, Uetrecht J. Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix. Med Hypotheses 1999;53:145-51
83. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 2002;58:265-74
84. International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia: a first report with special reference to analgesics. J Am Med Assoc 1986;256:1749-57
85. Gardner I, Leeder JS, Chin T, et al. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol Pharmacol 1998;53:999-1008
86. Pick AM, Nystrom KK. Nonchemotherapy Drug-induced neutropenia and agranulocytosis: could medications be the culprit? J Pharm Pract 2014;27:447-52
87. Huang CH, Li KL, Wu JH, et al. Antithyroid drug-induced agranulocytosis: report of 13 cases. Chang Gung Med J 2007;30:242-8
88. Akamizu T, Ozaki S, Hiratani H, et al. Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol 2002;127:92-8
89. Gilligan HM, Bredy B, Brady HR, et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996;184:2231-41
90. Fibbe WE, Claas FH, Van der Star-Dijkstra W, et al. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol 1986;64:363-73
91. Czuchlewski D R, Brackney M, Ewers C, et al. Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol 2010;133:466-72
92. Wolford A, McDonald TS, Eng H, et al. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. Drug Metab Dispos 2012;40:1067-75. Review
93. Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011;63:2209-14
94. Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol 2012;19:32-8. Review
95. Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of antitumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012;36:312-23. Review
96. Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 2005;23:247-50
97. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999;9:29-31
98. Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors GCSF and GM-CSF in the management of drug-induced agranulocytosis. Br J Haematol 2010;150:3-8
99. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 2004;14(6):459-62
100. Cohen D, Bogers JP, van Dijk D, et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012;73:1307-12. Review
101. Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1-/- mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 2014. [Epub ahead of print]